for only . The tender offer for all of the outstanding shares of common stock of Portola at a price of $18.00 per share expired as scheduled, one minute following 11:59 p.m., New York City time, on July 1, 2020. Monthly Subscription. $52.04. The daily trading volume for Portola Pharmaceuticals Inc. (NASDAQ:PTLA) over the last session is 4.69 million shares. The PE ratio measures the reported earnings of a company to its current stock price. 36.49. Portola Pharmaceuticals Stock Price . Price is a widely used stock evaluation measure. (RTTNews) - Alexion Pharmaceuticals, Inc. (ALXN) and Portola Pharmaceuticals, Inc. (PTLA) have entered into a definitive merger agreement for Alexion to acquire Portola… Price trends tend to persist, so it's worth looking at them when it comes to a share like Portola Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -33.23%. Most Recent Rating . Free trial. AstraZeneca has a portfolio of products for major diseases including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation areas.. Market capitalization of Portola Pharmaceuticals (PTLA) Market cap: $1.41 B As of March 2021 Portola Pharmaceuticals has a market cap of $1.41 B.This makes Portola Pharmaceuticals the world's 3470th most valuable company by market cap according to our data. SOUTH SAN FRANCISCO, Calif., Aug. 13, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of $28.00 per share. using the scroll bar or pinch and zoom on a touch screen). Note: We will be using adjusted close prices for calculations. Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10. Choose a Stash plan and set up your investment account in just a few minutes. Portola Pharmaceuticals, Inc. (PTLA) (Delayed Data from NSDQ) $36.49 USD. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) shareholders will doubtless be very grateful to see the share price up 152% in the last month.But over the last three years we’ve seen a quite serious decline. Under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola’s common stock at a price of $18 per share in cash. According to the announcement, the company estimates Andexxa revenues to be around $28 million for the fourth quarter. AstraZeneca plc (/ ˌ æ s t r ə ˈ z ɛ n ə k ə /) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters in Cambridge, England. for only. On January 9, 2020, Portola Pharmaceuticals announced that its preliminary unaudited Andexxa global net revenues came in far below estimates. Morgan Stanley does not see either upside or downside right now giving PTLA "Equal Weight" on their last update on May 08, 2020. Rare disease drugmaker Alexion will buy Portola Pharmaceuticals for $1.44 billion, the latest deal aimed at expanding its business beyond Soliris, its flagship product and top-selling therapy. The stock price has decreased by -31.91% in the last 52 weeks. DDE w/Realtime (Monthly) Monthly Subscription. Free trial. Q4 Andexxa/Ondexxya sales will be ~$32M. In the short term (2weeks), PTLA's stock price should underperform the market by -0.45%.During that period the price should oscillate between … The first section will let you know the impact on $1000 in Portola Pharmaceuticals Inc (PTLA) due to the share price changes. Follow PTLA. 2. Portola Pharmaceuticals Inc. [NASDAQ: PTLA] stock went on an upward path that rose over 0.17% on Wednesday, amounting to a one-week price increase of more than 0.06%. Big Cap Pro. The last trading period has seen Portola Pharmaceuticals Inc. (PTLA) move -44.06% and 234.27% from the stock’s 52-week high and 52-week low prices respectively. 645,483 +0.89 (2.50%) Updated May 3, 2019 04:00 PM ET. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer... | December 23, 2020 It opened the trading session at $17.94, the shares rose to $17.96 and dropped to $17.92, the range by which the price of stock traded the whole day. The price target was set to $14.00 → $18.00. Last 30 Days. The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." 11 )* Portola Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 737010108 … The following presents a detailed Portola Pharmaceuticals stock price history for your review. Monthly Subscription. In terms of volatility of its share price, PTLA is more volatile than 90.67% of stocks we're observing. for only. $34.10. Alexion is paying a healthy premium over Portola’s closing price on Tuesday. Portola Stock News: Stock drops over 40% on Andexxa Revenue Announcement . Portola Pharmaceuticals (NASDAQ:PTLA) slumps 39% after hours in reaction to preliminary Q4 and 2019 results that are significantly below consensus. Stock Price Statistics. Stocks with similar financial metrics, market capitalization, and price volatility to Portola Pharmaceuticals Inc are KALA, NSTG, DVAX, ORGS, and BGMD. $49.05. The average equity rating for PTLA stock is currently 2.70, trading … Use our historic performance chart to see real-time Portola Pharmaceuticals Inc stock price and the Portola Pharmaceuticals Inc news feed to help further your research before investing in fractional shares with any dollar amount you choose. After-Market: $36.46 (%) 5:22 PM ET. Historical Ratings. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Alexion will pay $18 per share for Portola, a roughly 130% premium over Portola's closing stock price on May 4. Portola Pharmaceuticals, Inc. Stock Price Forecast, "PTLA" Predictons for2021 Indeed, the share price is down a tragic 57% in the last three years. To help provide a sense of the short to long-term trend, included is an interactive Portola Pharmaceuticals stock chart which you can easily adjust to the time frame of your choosing (e.g. PTLA has attracted considerable attention from traders and investors, a scenario that has seen its volume jump … The beta is 2.31, so PTLA's price volatility has been higher than the market average. An important predictor of whether a stock price will go up is its track record of momentum. At this early stage in the launch, there is considerable uncertainty and guesswork involved in projecting sales. PTLA / Portola Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment. Visit PTLA's SEC page to see the company's official filings. PTLA stock forecast Our latest prediction for Portola Pharmaceuticals, Inc.'s stock price was made on the April 4, 2019 when the stock price was at 37.41$.. Implied Volatility Surging for Portola Pharmaceuticals (PTLA) Stock … (See Orchard’s stock analysis at TipRanks.) In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 1,205,357 shares from Portola … Portola Pharmaceuticals Stock Forecast NASDAQ:PTLA Price Target and Analyst Ratings. PTLA Stocks Year by Year Growth; Growth of 1000$ On PTLA Stock Vs S&P 500 Growth; Growth of 1000$ On PTLA Vs Gold ; 1 What would $1000 invested in Portola Pharmaceuticals Inc (PTLA) shares be worth now? 18.03 0.00 (0.0%) Upgrade to Real-Time Afterhours (Closed) Best deals to access real time data! Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. A high-level overview of Portola Pharmaceuticals, Inc. (PTLA) stock. Over the last 12 months, PTLA stock dropped by -31.71%. Add to portfolio. PTLA Price (Portola Pharmaceuticals stock price per share) $18.03 × PE Ratio Versus Sector. Portola Pharmaceuticals Inc. [NASDAQ: PTLA] loss 0.00% or 0.0 points to close at $17.94 with a heavy trading volume of 1150207 shares. Portola reported 2019 sales of $111.5 million for Andexxa, which is marketed as Ondexxya in Europe. VAT not included. Small Cap Pro. Read more. Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. Portola Pharmaceuticals Inc (NASDAQ: ... and the $15.17 average price target suggests a 124% upside from the current $6.76 trading price. While earnings are easy to manipulate on the balance sheet, this ratio gives you a sense of what buyers are willing to pay for the stock—what they believe it will do in the future. Portola is now a wholly owned subsidiary of Alexion. Free trial. K ey Conclusion The outlook for Portola’s stock price in 2019 and 2020 will almost certainly driven by the sales progress of Andexxa. 06-09 sec.gov - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. The one-year Portola Pharmaceuticals Inc. stock forecast points to a potential upside of 7.67.